Compare TNGX & TALKW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNGX | TALKW |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | 521 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | N/A |
| IPO Year | N/A | N/A |
| Metric | TNGX | TALKW |
|---|---|---|
| Price | $8.64 | $0.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $12.50 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 64.2K |
| Earning Date | 11-04-2025 | 02-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $66,501,000.00 | ★ $181,291,000.00 |
| Revenue This Year | $53.01 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.29 | 31.50 |
| 52 Week Low | $1.03 | $0.20 |
| 52 Week High | $11.20 | $0.24 |
| Indicator | TNGX | TALKW |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 41.97 |
| Support Level | $8.42 | $0.04 |
| Resistance Level | $10.08 | $0.07 |
| Average True Range (ATR) | 0.60 | 0.01 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 8.60 | 32.24 |
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.